Resolved1 update
Chikungunya Vaccine Suspension in US after reports of severe side effects
Story-level discussion
Start here
The United States has suspended the license for Ixchiq, a vaccine developed to fight the chikungunya virus, after new cases of severe side effects were reported. Valneva, the French company behind the vaccine, said the FDA made the decision last Friday. The move followed four fresh cases of adverse reactions. Three of
What happened
The United States has suspended the license for Ixchiq, a vaccine developed to fight the chikungunya virus, after new cases of severe side effects were reported. Valneva, the French company behind the vaccine, said the FDA made the decision last Friday. The move followed four fresh cases of adverse reactions. Three of
No updates yet on this story. Use the composer above to add the first node.